Avihu Tamir of Kanabo & Deepak Anand of Materia discuss the significance of commercial production licence

Justin Waite
Vox Markets Podcast with Justin Waite
07:47, 17th September 2021

AudioBoom Player

If you find this podcast useful please give it a rating and review on iTunes by clicking here  


Avihu Tamir of Kanabo & Deepak Anand of Materia discuss the significance of commercial production licence

Avihu Tamir CEO of Kanabo Group #KNB FOLLOW & Deepak Anand, CEO of Materia discuss the significance of the commercial production licence for their Malta facility.

Kanabo Group Plc (LSE:KNB), a medical cannabis R&D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, notes the recent announcement published by Materia. Kanabo are delighted that Materia's wholly-owned subsidiary, Materia Malta Operating Ltd. ("Materia Malta"), has received its Licence for the Production of Cannabis for Medicinal and Research Purposes (the "Licence") from the Malta Medicines Authority.

The receipt of the Licence is the final requirement for Materia Malta to begin commercial production and export of medical cannabis for commercial purposes. Materia Malta, which is already EU GMP certified, has an annual throughput capacity of 6,000kg, representing a potential sale value of €36M based on a blended average sales price across several key European markets.

Materia Malta has now begun the process of importing its first batch of raw material for commercial production and will begin fulfillment of its supply commitments across Europe imminently, starting with the initial target markets of Germany, Malta and the UK. The first product has already been successfully registered on the narcotics licence of Materia Deutschland GmbH ahead of its import into and across Germany.

About Kanabo Group Plc

Kanabo Group Plc is an R&D company currently selling a range of THC-Free Retail CBD Products in the Primary Markets and is in the process of developing further Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.  

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
Login or register to post comments

Recent Articles
Watchlist